Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study.

Edward C PortilloMichael PollackInyoung LeeKainan SunXiaohui ZhaoLisa KruseNorbert FeiglerSushma PatelAimee M Near

Published in: Therapeutic advances in respiratory disease (2023)

This real-world data analysis indicates that BGF is being initiated in patients with COPD experiencing symptoms and exacerbations despite current therapy, and among patients who have various chronic comorbidities, most often cardiopulmonary-related.

Keyphrases

chronic obstructive pulmonary disease
data analysis
lung function
stem cells
sleep quality
physical activity
drug induced
depressive symptoms
bone marrow
mesenchymal stem cells